Stockreport

23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024 [Yahoo! Finance]

23andMe Holding Co.  (ME) 
PDF ULBP6 and mechanism of 23ME-01473, and new non-clinical insights for 23ME-00610, targeting the CD200R1 pathway SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSW [Read more]